These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 386308

  • 1. A review of some aspects of the pharmacology of levodopa.
    Morris JG.
    Clin Exp Neurol; 1978; 15():24-50. PubMed ID: 386308
    [Abstract] [Full Text] [Related]

  • 2. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E.
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract] [Full Text] [Related]

  • 3. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [Abstract] [Full Text] [Related]

  • 4. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986 Jul; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F.
    Adv Neurol; 1990 Jul; 53():83-100. PubMed ID: 1978522
    [No Abstract] [Full Text] [Related]

  • 6. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS, Fisher A, Starr MS.
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [Abstract] [Full Text] [Related]

  • 7. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS, Starr MS.
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [Abstract] [Full Text] [Related]

  • 8. The drug treatment of Parkinson's disease.
    Morris JG.
    Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767
    [Abstract] [Full Text] [Related]

  • 9. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP, Rüther E.
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract] [Full Text] [Related]

  • 10. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T, Knott P, Kaufmann H, Yahr M.
    Adv Neurol; 1990 Feb; 53():75-81. PubMed ID: 2173378
    [No Abstract] [Full Text] [Related]

  • 11. [Drug therapy in Parkinson's disease].
    van Hilten JJ, Roos RA.
    Ned Tijdschr Geneeskd; 1999 Jan 30; 143(5):234-40. PubMed ID: 10086151
    [Abstract] [Full Text] [Related]

  • 12. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Brain Res Rev; 2006 Sep 30; 52(2):244-56. PubMed ID: 16644019
    [Abstract] [Full Text] [Related]

  • 13. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O.
    Neurodegener Dis; 2008 Sep 30; 5(3-4):114-7. PubMed ID: 18322366
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S, Muñetón-Gómez VC, de Ceballos ML, Bernson M, Moratalla R.
    Eur J Neurosci; 2008 Feb 30; 27(3):580-92. PubMed ID: 18279311
    [Abstract] [Full Text] [Related]

  • 15. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A.
    J Neural Transm Suppl; 1983 Feb 30; 19():153-61. PubMed ID: 6321646
    [Abstract] [Full Text] [Related]

  • 16. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F.
    Mov Disord; 2004 Sep 30; 19(9):997-1005. PubMed ID: 15372588
    [Abstract] [Full Text] [Related]

  • 17. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T.
    Nervenarzt; 2003 Mar 30; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [Abstract] [Full Text] [Related]

  • 18. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984 Mar 30; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.